Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan
In Vivo. 2019 Nov-Dec;33(6):2013-2019. doi: 10.21873/invivo.11698.
Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis.
We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital.
Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%).
Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.
背景/目的：我们评估了在高级肾细胞癌伴下腔静脉肿瘤血栓患者中，行肾切除术和血栓切除术联合与不联合术前帕唑帕尼治疗的手术结果。
我们比较了在神户大学医院接受手术治疗的 19 例高级肾细胞癌伴高水平下腔静脉肿瘤血栓患者中，行术前帕唑帕尼治疗与单纯手术治疗的患者的手术结果。
与单纯手术组相比，术前组的平均手术时间分别为 497 分钟和 627 分钟（p=0.08）；平均出血量分别为 1928 毫升和 7393 毫升（p<0.05）；平均术后住院时间分别为 15.3 天和 21.6 天（p=0.05）；且围手术期并发症发生率较低（术前组：33%比手术组：50%）。
术前使用帕唑帕尼治疗可降低高级肾细胞癌伴高水平下腔静脉肿瘤血栓的手术难度，改善手术结果。
